nach oben

The Cerebellum

Erschienen in:

01.10.2014 | Original Paper

Glutamate and GABA-Metabolizing Enzymes in Post-mortem Cerebellum in Alzheimer’s Disease: Phosphate-Activated Glutaminase and Glutamic Acid Decarboxylase

verfasst von: G. Sh. Burbaeva, I. S. Boksha, E. B. Tereshkina, O. K. Savushkina, T. A. Prokhorova, E. A. Vorobyeva

Erschienen in: The Cerebellum | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Enzymes of glutamate and GABA metabolism in postmortem cerebellum from patients with Alzheimer’s disease (AD) have not been comprehensively studied. The present work reports results of original comparative study on levels of phosphate-activated glutaminase (PAG) and glutamic acid decarboxylase isoenzymes (GAD65/67) in autopsied cerebellum samples from AD patients and matched controls (13 cases in each group) as well as summarizes published evidence for altered levels of PAG and GAD65/67 in AD brain. Altered (decreased) levels of these enzymes and changes in links between amounts of these enzymes and other glutamate-metabolizing enzymes (such as glutamate dehydrogenase and glutamine synthetase-like protein) in AD cerebella suggest significantly impaired glutamate and GABA metabolism in this brain region, which was previously regarded as not substantially involved in AD pathogenesis.

Fujiwara T, Morimoto K. A compound CP-31398 suppresses excitotoxicity-induced neurodegeneration. Biochem Biophys Res Commun. 2013;440(3):359–63.PubMedCrossRef

Hoey SE, Buonocore F, Cox CJ, Hammond VJ, Perkinton MS, Williams RJ. AMPA receptor activation promotes non-amyloidogenic amyloid precursor protein processing and suppresses neuronal amyloid-β production. PLoS One. 2013;8(10):e78155. doi:10.1371/journal.pone.0078155.PubMedCentralPubMedCrossRef

Wang ZC, Zhao J, Li S. Dysregulation of synaptic and extrasynaptic N-methyl-D-aspartate receptors induced by amyloid-β. Neurosci Bull. 2013;29(6):752–60.PubMedCrossRef

Majláth Z, Toldi J, Vécsei L. The potential role of kynurenines in Alzheimer’s disease: pathomechanism and therapeutic possibilities by influencing the glutamate receptors. J Neural Transm. 2013. doi:10.1007/s00702-013-1135-5.PubMed

Jones RS, Waldman AD. 1H-MRS evaluation of metabolism in Alzheimer’s disease and vascular dementia. Neurol Res. 2004;26(5):488–95.PubMedCrossRef

Boksha IS. Coupling between neuronal and glial cells via glutamate metabolism in brain of healthy persons and patients with mental disorders. Biochemistry (Mosc). 2004;69(7):705–19.CrossRef

Burbaeva GS, Boksha IS, Tereshkina EB, Savushkina OK, Starodubtseva LI, Turishcheva MS. Glutamate metabolizing enzymes in prefrontal cortex of Alzheimer’s disease patients. Neurochem Res. 2005;30(11):1443–51.PubMedCrossRef

Olabarria M, Noristani HN, Verkhratsky A, Rodríguez JJ. Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer’s disease mouse model: mechanism for deficient glutamatergic transmission? Mol Neurodegener. 2011;6:55–63.PubMedCentralPubMedCrossRef

Adeva MM, Souto G, Blanco N, Donapetry C. Ammonium metabolism in humans. Metabolism. 2012;61(11):1495–511.PubMedCrossRef

10.

Albrecht J, Norenberg MD. Glutamine: a Trojan horse in ammonia neurotoxicity. Hepatology. 2006;44(4):788–94.PubMedCrossRef

11.

Albrecht J, Sonnewald U, Waagepetersen HS, Schousboe A. Glutamine in the central nervous system: function and dysfunction. Front Biosci. 2007;1(12):332–43.CrossRef

12.

Bae N, Wang Y, Li L, Rayport S, Lubec G. Network of brain protein level changes in glutaminase deficient fetal mice. J Proteomics. 2013;27(80):236–49.CrossRef

13.

Dumanis SB, DiBattista AM, Miessau M, Moussa CE, Rebeck GW. APOE genotype affects the pre-synaptic compartment of glutamatergic nerve terminals. J Neurochem. 2013;124(1):4–14.PubMedCentralPubMedCrossRef

14.

Vermeiren Y, Van Dam D, Aerts T, Engelborghs S, De Deyn PP. Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer’s disease. J Alzheimer’s Dis. 2014 Mar 31.

15.

O’Halloran CJ, Kinsella GJ, Storey E. The cerebellum and neuropsychological functioning: a critical review. J Clin Exp Neuropsychol. 2012;34(1):35–56.PubMedCrossRef

16.

Holten AT, Gundersen V. Glutamine as a precursor for transmitter glutamate, aspartate and GABA in the cerebellum: a role for phosphate-activated glutaminase. J Neurochem. 2008;104(4):1032–42.PubMedCrossRef

17.

Burbaeva GS, Savushkina OK, Dmitriev AD. Brain isoforms of creatine kinase in health and mental diseases: Alzheimer’s disease and schizophrenia. Vestn Ross Akad Med Nauk. 1999;1:20–4 [Russian].PubMed

18.

Burbaeva GSh, Savushkina OK, Boksha IS. Comparative study of creatine kinase BB decrease in brain of patients with Alzheimer’s disease and schizophrenia. In: Kekelidze T, Holtzman D, editors. Creatine kinase and brain energy metabolism. NATO Science Series, 342, Netherlands: IOS Press; 2003. p. 125–132.

19.

Burbaeva GS, Turishcheva MS, Vorobyeva EB, Savushkina OK, Tereshkina EB, Boksha IS. Diversity of glutamate dehydrogenase in human brain. Prog Neuropsyhopharmacol Biol Psychiatry. 2002;26(3):427–35.CrossRef

20.

Buddhala C, Suarez M, Modi J, Prentice H, Ma Z, Tao R, et al. Calpain cleavage of brain glutamic acid decarboxylase 65 is pathological and impairs GABA neurotransmission. PLoS One. 2012;7(3):e33002.PubMedCentralPubMedCrossRef

21.

Kaneko T, Itoh K, Shigemoto R, Mizuno N. Glutaminase-like immunoreactivity in the lower brain stem and cerebellum of the adult rat. Neuroscience. 1989;32(1):79–98.PubMedCrossRef

22.

Levi G, Gallo V. Glutamate as a putative transmitter in the cerebellum: stimulation by GABA of glutamic acid release from specific pools. J Neurochem. 1981;37(1):22–31.PubMedCrossRef

23.

Kvamme E, Roberg B, Torgner IA. Phosphate-activated glutaminase and mitochondrial glutamine transport in the brain. Neurochem Res. 2000;25(9–10):1407–19.PubMedCrossRef

24.

Kvamme E, Torgner IA, Roberg B. Kinetics and localization of brain phosphate activated glutaminase. J Neurosci Res. 2001;66(5):951–8.PubMedCrossRef

25.

Roberg B, Torgner IA, Laake J, Takumi Y, Ottersen OP, Kvamme E. Properties and submitochondrial localization of pig and rat renal phosphate-activated glutaminase. Am J Physiol Cell Physiol. 2000;279(3):C648–57.PubMed

26.

Kvamme E, Nissen-Meyer LS, Roberg BA, Torgner IA. Novel form of phosphate activated glutaminase in cultured astrocytes and human neuroblastoma cells, PAG in brain pathology and localization in the mitochondria. Neurochem Res. 2008;33(7):1341–5.PubMedCrossRef

27.

Shimmura C, Suzuki K, Iwata Y, Tsuchiya KJ, Ohno K, Matsuzaki H, et al. Enzymes in the glutamate glutamine cycle in the anterior cingulate cortex in postmortem brain of subjects with autism. Mol Autism. 2013;4(1):6–13.PubMedCentralPubMedCrossRef

28.

Akiyama H, McGeer PL, Itagaki S, McGeer EG, Kaneko T. Loss of glutaminase-positive cortical neurons in Alzheimer’s disease. Neurochem Res. 1989;14(4):353–8.PubMedCrossRef

29.

Haug LS, Ostvold AC, Cowburn RF, Garlind A, Winblad B, Bogdanovich N, et al. Decreased inositol (1,4,5)-trisphosphate receptor levels in Alzheimer’s disease cerebral cortex: selectivity of changes and possible correlation to pathological severity. Neurodegeneration. 1996;5(2):169–76.PubMedCrossRef

30.

Lynn BC, Wang J, Markesbery WR, Lovell MA. Quantitative changes in the mitochondrial proteome from subjects with mild cognitive impairment, early stage and late stage Alzheimer’s disease. J Alzheimers Dis. 2010;19(1):325–39.PubMedCentralPubMed

31.

Monnerie H, Le Roux PD. Glutamate alteration of glutamic acid decarboxylase (GAD) in GABA ergic neurons: the role of cysteine proteases. Exp Neurol. 2008;213(1):145–53.PubMedCrossRef

32.

Turský T, Lassánová M. Inhibition of different molecular forms of brain glutamic acid decarboxylase (GAD) with ATP. J Neurochem. 1978;30(4):903–5.PubMedCrossRef

33.

Erlander MG, Tobin AJ. The structural and functional heterogeneity of glutamic acid decarboxylase: a review. Neurochem Res. 1991;16(3):215–26.PubMedCrossRef

34.

Esclapez M, Tillakaratne NJK, Kaufman DL, Tobin AJ, Houser CR. Comparative localization of two forms of glutamic acid decarboxylase and their mRNAs in rat brain supports the concept of functional differences between the forms. J Neurosci. 1994;14(3):1834–55.PubMed

35.

Tian N, Petersen C, Kash S, Baekkeskov S, Copenhagen D, Nicoll R. The role of the synthetic enzyme GAD65 in the control of neuronal gamma-aminobutyric acid release. Proc Natl Acad Sci U S A. 1999;96:12911–6.PubMedCentralPubMedCrossRef

36.

Wei J, Wu J-Y. Post-translational regulation of L-glutamic acid decarboxylase in the brain. Neurochem Res. 2008;33:1459–65.PubMedCrossRef

37.

Martin DL, Martin SB, Wu SJ, Espina N. Cofactor interactions and the regulation of glutamate decarboxylase activity. Neurochem Res. 1991;16(3):243–9.PubMedCrossRef

38.

Fenalti G, Law RH, Buckle AM, Langendorf C, Tuck K, Rosado CJ, et al. GABA production by glutamic acid decarboxylase is regulated by a dynamic catalytic loop. Nat Struct Mol Biol. 2007;14:280–6.PubMedCrossRef

39.

Kaufman DL, Houser CR, Tobin A. Two forms of the aminobutyric acid synthetic enzyme glutamate decarboxylase have distinct intraneuronal distribution and cofactor interaction. J Neurochem. 1991;56:720–3.PubMedCrossRef

40.

Owens D, Kriegstein A. Is there more to GABA than synaptic inhibition? Nat Rev Neurosci. 2002;3:715–27.PubMedCrossRef

41.

Asada H, Kawamura Y, Maruyama K. Mice lacking the 65 kDa isoform of glutamic acid decarboxylase (GAD65) maintain normal levels of GAD67 and GABA in their brains but are susceptible to seizures. Biochem Biophys Res Commun. 1996;229:891–5.PubMedCrossRef

42.

Asada H, Kawamura Y, Maruyama K. Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase. Proc Natl Acad Sci U S A. 1997;94(12):6496–9.PubMedCentralPubMedCrossRef

43.

Schwab C, Yu S, Wong W, McGeer EG, McGeer PL. GAD65, GAD67, and GABAT immunostaining in human brain and apparent GAD65 loss in Alzheimer’s disease. J Alzheimers Dis. 2013;33(4):1073–88.PubMed

44.

Dirkx Jr R, Thomas A, Li L, Lernmark A, Sherwin RS, De Camilli P, et al. Targeting of the 67-kDa isoform of glutamic acid decarboxylase to intracellular organelles is mediated by its interaction with the NH₂-terminal region of the 65-kDa isoform of glutamic acid decarboxylase. J Biol Chem. 1995;270:2241–6.PubMedCrossRef

45.

Kanaani J, Lissin D, Kash SF, Baekkeskov S. The hydrophilic isoform of glutamate decarboxylase, GAD67, is targeted to membranes and nerve terminals independent of dimerization with the hydrophobic membrane-anchored isoform, GAD65. J Biol Chem. 1999;274(52):37200–9.PubMedCrossRef

46.

Mitew S, Kirkcaldie MT, Dickson TC, Vickers JC. Altered synapses and gliotransmission in Alzheimer’s disease and AD model mice. Neurobiol Aging. 2013;34(10):2341–51.PubMedCrossRef

47.

Krantic S, Isorce N, Mechawar N, Davoli MA, Vignault E, Albuquerque M, et al. Hippocampal GABAergic neurons are susceptible to amyloid-β toxicity in vitro and are decreased in number in the Alzheimer’s disease TgCRND8 mouse model. J Alzheimers Dis. 2012;29(2):293–308.PubMed

48.

Sjöbeck M, Englund E. Alzheimer’s disease and the cerebellum: a morphologic study on neuronal and glial changes. Dement Geriatr Cogn Disord. 2001;12(3):211–8.PubMedCrossRef

49.

Bowen DM, White P, Flack RH, Smith CB, Davison AN. Brain-decarboxylase activities as indices of pathological change in senile dementia. Lancet. 1974;1(7869):1247–9.PubMedCrossRef

50.

Reinikainen KJ, Paljärvi L, Huuskonen M, Soininen H, Laakso M, Riekkinen PJ. A postmortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer’s disease. J Neurol Sci. 1988;84(1):101–16.PubMedCrossRef

51.

Boissière F, Faucheux B, Duyckaerts C, Hauw JJ, Agid Y, Hirsch EC. Striatal expression of glutamic acid decarboxylase gene in Alzheimer’s disease. J Neurochem. 1988;71(2):767.CrossRef

52.

Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci. 1977;34(2):247–65.PubMedCrossRef

53.

Gluck MR, Thomas RG, Davis KL, Haroutunian V. Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. Am J Psychiatry. 2002;159(7):1165–11673.PubMedCrossRef

54.

Yates CM, Butterworth J, Tennant MC, Gordon A. Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias. J Neurochem. 1990;55(5):1624–30.PubMedCrossRef

55.

Monfort JC, Javoy-Agid F, Hauw JJ, Dubois B, Agid Y. Brain glutamate decarboxylase in Parkinson’s disease with particular reference to a premortem severity index. Brain. 1985;108(2):301–13.PubMedCrossRef

56.

Simpson MD, Cross AJ, Slater P, Deakin JF. Loss of cortical GABA uptake sites in Alzheimer’s disease. J Neural Transm. 1988;71(3):219–26.PubMedCrossRef

57.

Bland R, Fitzsimons H. Novel glutamic acid decarboxylase (GAD) chimera and methods of use. USA Patent US8071563 B2. 2009

58.

Whitelaw BS, Robinson MB. Inhibitors of glutamate dehydrogenase block sodium-dependent glutamate uptake in rat brain membranes. Front Endocrinol (Lausanne). 2013;4:123.

59.

Bauer DE, Jackson JG, Genda EN, Montoya MM, Yudkoff M, Robinson MB. The glutamate transporter, GLAST, participates in a macromolecular complex that supports glutamate metabolism. Neurochem Int. 2012;61(4):566–74.PubMedCentralPubMedCrossRef

60.

Middleton FA, Strick PL. Cerebellar projections to the prefrontal cortex of the primate. J Neurosci. 2001;21(2):700–12.PubMed

61.

Schmahmann JD. The role of the cerebellum in cognition and emotion: personal reflections since 1982 on the dysmetria of thought hypothesis, and its historical evolution from theory to therapy. Neuropsychol Rev. 2010;20(3):236–60.PubMedCrossRef

62.

Timmann D, Daum I. Cerebellar contributions to cognitive functions: a progress report after two decades of research. Cerebellum. 2007;6(3):159–62.PubMedCrossRef

63.

Arnsten AF, Rubia K. Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders. J Am Acad Child Adolesc Psychiatry. 2012;51(4):356–67.PubMedCrossRef

64.

Konarski JZ, McIntyre RS, Grupp LA, Kennedy SH. Is the cerebellum relevant in the circuitry of neuropsychiatric disorders? J Psychiatry Neurosci. 2005;30(3):178–86.PubMedCentralPubMed

65.

Chen J, Cohen ML, Lerner AJ, Yang Y, Herrup K. DNA damage and cell cycle event simplicate cerebellar dentate nucleus neurons as targets of Alzheimer’s disease. Mol Neurodegener. 2010;20(5):60–71.CrossRef

Titel: Glutamate and GABA-Metabolizing Enzymes in Post-mortem Cerebellum in Alzheimer’s Disease: Phosphate-Activated Glutaminase and Glutamic Acid Decarboxylase
verfasst von: G. Sh. Burbaeva
I. S. Boksha
E. B. Tereshkina
O. K. Savushkina
T. A. Prokhorova
E. A. Vorobyeva
Publikationsdatum: 01.10.2014
Verlag: Springer US
Erschienen in: The Cerebellum / Ausgabe 5/2014
Print ISSN: 1473-4222
Elektronische ISSN: 1473-4230
DOI: https://doi.org/10.1007/s12311-014-0573-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2014

Severe Hypomagnesaemia Causing Reversible Cerebellopathy

Development of External Surfaces of Human Cerebellar Lobes in the Fetal Period

The Association of RAB18 Gene Polymorphism (rs3765133) with Cerebellar Volume in Healthy Adults

Focused Cerebellar Laser Light Induced Hyperthermia Improves Symptoms and Pathology of Polyglutamine Disease SCA1 in a Mouse Model

The Moonwalker Mouse: New Insights into TRPC3 Function, Cerebellar Development, and Ataxia